Heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
This was Merck's first use of the designation and the reduction in regulatory risk was one of the reasons management was willing to put company resources into development. In 2013, the United States Adopted Name (USAN) name was changed from lambrolizumab to pembrolizumab. In that year clinical trial results in advanced melanoma were published in The New England Journal of Medicine. This was part of the large phase I NCT01295827 trial. In September 2014, the US Food and Drug Administration (FDA) approved pembrolizumab under the Fast Track Development Program. It is approved for use following treatment with ipilimumab, or after treatment with ipilimumab and a BRAF inhibitor in advanced melanoma patients who carry a BRAF mutation. As of 2015, the only PD-1/PD-L1 targeting drugs on the market are pembrolizumab and nivolumab. By April 2016, Merck applied for approval to market the drug in Japan and signed an agreement with Taiho Pharmaceutical to co-promote it there. In July 2015, pembrolizumab received marketing approval in the European Union. In October 2015, the US FDA approved pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC) in people whose tumors express PD-L1 and who have failed treatment with other chemotherapeutic agents. In July 2016, the US FDA accepted for priority review an application for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after a platinum-based chemotherapy.
The debate over AI developers training models on copyrighted material without consent is highly contentious in the UK. In 2024, the government proposed a broad text and data mining (TDM) exception allowing AI companies to use publicly available copyrighted material. This faced intense opposition from the creative sector. In March 2026, the House of Lords Communications and Digital Committee concluded that generative AI poses a "clear and present danger" to the creative industries. Trade unions campaigned against the proposals, leading the government to abandon the "opt-out" model. The government acknowledged the need to build an evidence base before reforming copyright law.
Due in large part to the success of these tests, assessment was to become the core discipline of clinical psychology for the next quarter-century, when another war would propel the field into treatment.
Sources: en.wikipedia.org
=== Positive effects === As the public becomes more aware of the stereotypical nature of mental illness depictions, there is an increasing number of studies being done to examine how media messages can positively affect audiences by decreasing stigma. Research has found that news stories are much more likely to produce positive audience comments and reactions if they use counter-stigmatism in their storytelling rather than stereotypes and discriminatory language. In a more specific sense, media portraying a realistic account of mental illness can give medical professionals a glimpse into the life and realities of living with such an illness. The research regarding the educational aspects of the film for nurse students from all fields suggested that the films of different genres, including life stories, adventures, and others, provided practical insights into understanding the patient experience and perspectives in different environments. Another research also found the positive aspects of the movies for educational purposes on students in medical (clinical) fields. The films provide valuable lessons for individuals in understanding the specific cases and appropriate treatment plans for patients. Even though there are some concerns that movies are not intended for educational purposes but for entertainment, researchers suggest that films provide positive outcomes in students' learning experiences.
==== "Smart" hydrogel dressings ==== "Smart" hydrogels which are stimuli-responsive (i.e. thermoresponsive, bioresponsive, pH-responsive, photoresponsive, and redox-responsive) are also being produced.
Flight cases and transit cases are usually custom designed for shipping and carrying fragile equipment: audio visual, camera, instruments, etc. Although generally light in construction, they tend to have reinforced edges and corners.
Sources: en.wikipedia.org
For the second consecutive year, the AFL's opening round was spread across two weekends. Due to concern over one-sided matches, each of the top four teams from 2012 (Sydney, Hawthorn, Adelaide and Collingwood) played each of the bottom four teams (the Western Bulldogs, Melbourne, Gold Coast and Greater Western Sydney) only once each – except that Sydney played local rival Greater Western Sydney twice, and that the Western Bulldogs played Adelaide twice. None of the bottom five teams from 2012 (Western Bulldogs, Port Adelaide, Melbourne, Gold Coast and Greater Western Sydney) featured in a Friday night match during the home-and-away season. This is due to the AFL's policy of awarding Friday night matches only to teams that perform consistently throughout the season. This season was the last in which AFL football was played at AAMI Stadium, with both Adelaide and Port Adelaide moving to a redeveloped Adelaide Oval from the 2014 season. Match starting times are local.
Sildenafil is available as a generic drug in the United States, labeled for pulmonary arterial hypertension, and to treat erectile dysfunction, as the patent expired in April 2020. In the US, Revatio and Viagra are marketed by Viatris after Upjohn was spun off from Pfizer.
==== Discoveries ==== The chemosynthetic communities of the Gulf of Mexico have been studied extensively since the 1990s, and communities first discovered on the upper slope are likely the best understood seep communities in the world. The history of the discovery of these remarkable animals has all occurred since the 1980s. Each major discovery was unexpected―from the first hydrothermal vent communities anywhere in the world to the first cold seep communities in the Gulf of Mexico. Communities were discovered in the eastern Gulf of Mexico in 1983 using the crewed submersible DSV Alvin, during a cruise investigating the bottom of the Florida Escarpment in areas of "cold" brine seepage, where they unexpectedly discovered tubeworms and mussels. Two groups fortuitously discovered chemosynthetic communities in the central Gulf of Mexico nearly concurrently in November and December 1984. During investigations in late December on the research vessel R/V Gyre cruise 84-G-12, by Texas A&M University, two bottom trawls were conducted to determine the effects of oil seepage on benthic ecology (until this investigation, all effects of oil seepage were assumed to be detrimental). Trawls unexpectedly recovered extensive collections of chemosynthetic organisms, including tubeworms and clams. a month earlier, LGL Ecological Research Associates was conducting a research cruise as part of the multiyear MMS Northern Gulf of Mexico Continental Slope Study (Gallaway et al., 1988).
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.